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Abstract
Diagnostic methods for biliary tract carcinoma and the efﬁ  -
cacy of these methods are discussed. Neither deﬁ  nite methods 
for early diagnosis nor speciﬁ  c markers are available in this 
disease. When this disease is suspected on the basis of clinical 
symptoms and risk factors, hemato-biochemical examination 
and abdominal ultrasonography are performed and, where 
appropriate, enhanced computed tomography (CT) and/or 
magnetic resonance cholangiopancreatography (MRCP) is 
carried out. Diagnoses of extrahepatic bile duct cancer and 
ampullary carcinoma are often made based on the presence 
of obstructive jaundice. Although rare, abdominal pain and 
pyrexia, as well as abnormal ﬁ  ndings of the hepatobiliary 
system detected by hemato-biochemical examination, serve as 
a clue to making a diagnosis of these diseases. On the other 
hand, the early diagnosis of gallbladder cancer is scarcely pos-
sible on the basis of clinical symptoms, so when this cancer is 
found with the onset of abdominal pain and jaundice, it is 
already advanced at the time of detection, thus making a cure 
difﬁ  cult. When gallbladder cancer is suspected, enhanced CT 
is carried out. Multidetector computed tomography (MDCT), 
in particular — one of the methods of enhanced CT — is 
useful for decision of surgical criteria, because MDCT shows 
ﬁ  ndings such as localization and extension of the tumor, and 
the presence or absence of remote metastasis. Procedures such 
as magnetic resonance imaging, endoscopic ultrasonography, 
bile duct biopsy, and cholangioscopy should be carried out 
taking into account indications for these procedures in indi-
vidual patients. However, direct biliary tract imaging is neces-
sary for making a precise diagnosis of the horizontal extension 
of bile duct cancer.
Key words Biliary tract neoplasm · Endoscopic ultrasonogra-
phy (EUS) · Multidetector computed tomography (MDCT) · 
Guidelines
Introduction
Of biliary tract cancers, extrahepatic bile duct cancer 
and carcinoma of the papilla are often diagnosed 
with the onset of obstructive jaundice. In only a few 
cases is a diagnosis of these cancers made prior to the 
onset of jaundice, based on a detailed examination 
of symptoms of cholangitis. Also, a diagnosis of 
biliary tract cancer is occasionally made in a patient 
without symptoms, on the basis of abnormal results on 
hemato-biochemical examination of the hepatobiliary 
system. Although some risk factors for biliary tract 
cancer have been indicated, neither an algorithm for 
early diagnosis nor hemato-biochemical examinations, 
nor clinical symptoms and tumor markers that are 
speciﬁ  c to this disease are available. As far as gall-
bl  adder cancer is concerned, it is already advanced 
at the time when its diagnosis has been made, based 
on the presence of abdominal pain and jaundice. The 
ﬁ  rst step in the diagnostic imaging of biliary tract 
cancer is abdominal ultrasonography; enhanced 
computed tomography (multidetector CT where 
available) is carried out for patients with suspected 
biliary tract tumors. Magnetic resonance imaging 
(MRI, including magnetic resonance cholangiopan-
creatography [MRCP]) has come into increased use 
as an alternative procedure for direct biliary tract 
imaging, and is indispensable in making a precise diag-
nosis of horizontal extension. Other excellent diag-
nostic procedures include endoscopic ultrasonography, 
bile duct biopsy (cytologic diagnosis), and cholangios-
copy. These should be used with care as test procedures 
prior to treatment while paying attention to the symp-
toms of individual patients. As guidelines for the 
diagnosis of gallbladder cancer, this article poses ﬁ  ve 
clinical questions (CQs), in addition to a providing a 
literature review related to each of these questions. In 
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the responses to the CQs, recommendations for treat-
ment are noted (grades of these recommendations are 
deﬁ  ned in Table 1
1). Also, levels of evidence are given 
(in parentheses) for ﬁ  ndings in reference citations (see 
deﬁ  nitions of levels in Table 2
1).
CQ 1 By which clinical symptoms is biliary tract 
cancer suspected?
When jaundice, right upper abdominal pain, and 
abnormal ﬁ  ndings detected by hemato-biochemical 
examination of the hepatobiliary system have been 
observed, examination should be carried out, bearing 
biliary tract carcinoma in mind (recommendation 
B).
In 90% of patients with bile duct cancer, the initial 
symptom is jaundice
2  (level VI). Other symptoms, 
including pruritus, mild upper abdominal pain, and 
weight loss are found in more than half of the patients 
with this cancer
2–4 (level VI). There is a report that, in 
patients without jaundice, abdominal pain is present 
in 44% of these patients, pyrexia in 17%, anorexia in 
11%, and general lassitude in 11% as initial symptoms, 
but that 27% of the patients (level IV) have no 
symptoms.
5
The clinical symptom observed most frequently in 
gallbladder cancer is right upper abdominal pain, in 
79%–89% of the patients,
6–8 followed by nausea/vomit-
ing, in 52%–53%,
6,7  and other signs and symptoms, 
such as weight loss, jaundice, anorexia, abdominal dis-
tention, pruritus, and tarry stools
6 (level IV). Many of 
these patients have such complications as cholecystoli-
CQ 2  What is the ﬁ  rst step in the diagnosis of biliary 
tract cancer?
Noninvasive abdominal ultrasonography and 
hematological examination can be the ﬁ  rst step in 
diagnosis (recommendation B).
Hemato-biochemical examination
Liver dysfunction is present in patients with bile duct 
obstruction.(increases in alkaline phosphatase, γ-
glutamyl transpeptidase, and total bilirubin)
12,13 (level 
III), but no speciﬁ  c hemato-biochemical examination to 
diagnose biliary tract carcinoma is available.
Abdominal ultrasonography (abdominal US; 
see Figs 1–3)
The diagnostic imaging to be performed in the ﬁ  rst 
place is abdominal US when biliary tract cancer is sus-
pected. Particularly, this procedure facilitates the detec-
tion of dilated intrahepatic bile ducts (Fig. 1a), thus 
enabling assessment of the obstructed site
12,13 (level III). 
Fifty percent of gallbladder cancers cases are depicted 
as tumors on abdominal US (Fig. 3).
11
The detectability of bile duct cancer varies from 21% 
to 90% (Figs. 1b, 2)
2,5,14,16 and the detectability of distal 
Table 1.  Strength of recommendations
1
A, Strongly recommend performing the clinical action
B, Recommend performing the clinical action
C1, The clinical action may be considered although there is a 
lack of high-level scientiﬁ  c evidence for its use. May be 
useful
C2, Clinical action not deﬁ  nitively recommended because of 
insufﬁ  cient scientiﬁ  c evidence. Evidence insufﬁ  cient to 
support or deny usefulness
D, Recommend not performing the clinical action
Table 2.  Levels of evidence
1
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
patient’s data
thiasis and anomalous arrangement of pancreatico-
biliary ducts, so it cannot be denied that the above 
mentioned clinical symptoms have occurred due to 
these complications. Thus, it may be difﬁ  cult to con-
clude that they are speciﬁ  c symptoms induced by gall-
bladder cancer.
The clinical symptoms frequently encountered in 
ampullary carcinoma are jaundice, pyrexia, abdominal 
pain followed by general lassitude, weight loss, anorexia, 
and back pain. Jaundice is reported to be observed 
in 72%–90% of these patients
9–11 (levels IV, VI), but it 
is characterized by occasional ﬂ  uctuation
11 (level VI). 
There is a report that pyrexia is present in 44%
11 (level 
IV) and abdominal pain occurs in 45% of patients
10 
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Carbohydrate antigen 19-9 (CA19-9)
17–21 (levels II, III)
CA19-9 is not evident to conﬁ  rm of diagnosis in patients 
with suspected biliary tract cancer. However:
•   It is increased in 50%–79% of patients with biliary 
tract cancer.
•    It also increases in patients with cholestasis.
• It does not increase in patients with biliary tract 
cancer if sialyl Le
a is negative.
Carcinoembryonic antigen (CEA)
17,21–23 (level III)
•    CEA is increased in 40%–70% of patients with biliary 
tract cancer.
•    Cholestasis has no impact on CEA.
Cancer antigen 125 (CA125)
21,24 (level IV)
•    CA125 is increased in 58% of patients with gallblad-
der cancer (17 U/ml as the cutoff point).
•  It tends to increase in patients with ascites.
Although the values of other markers, including 
DUPAN-2, CA195, CA242, and interleukin (IL)-6 are 
occasionally measured, their clinical usefulness is not 
clear
21 (level II).
ab
Fig. 1.  Extracorporeal ultrasonography (US) images of a case 
of cancer in the hepatic hilar bile duct, showing dilated right 
intrahepatic bile duct (a), but imaging of hepatic hilar tumor 
is poor (indirect ﬁ  ndings showing the presence of tumor) (b)
Fig. 2.  Extracorporeal US image of a case of middle bile duct 
cancer, showing blockage of the bile duct due to the tumor in 
the superior margin of the pancreas head (direct ﬁ  nding of 
tumor)
Fig. 3.  Extracorporeal US image of an advanced gallbladder 
cancer (wall-thickness type), showing advanced gallbladder 
cancer with circumferential wall thickness
CQ 3  What is the second step in the diagnosis of bile 
duct cancer?
CT and MRI (including MRCP) are useful for 
localization of the lesion and assessment of the 
degree of its extension (recommendation B). Also, 
direct cholangiography is useful for the diagnosis of 
the horizontal extension of bile duct cancer 
(recommendation C1).
bile duct carcinoma is low. When dilatation of the intra-
hepatic bile duct without extrahepatic bile duct dilata-
tion is observed, stricture of the hilar bile duct is 
suspected (Fig. 1a,b), but middle and lower bile duct 
stricture is suspected when both intrahepatic and extra-
hepatic bile ducts are dilated
2,5,14–16 (level IV).
Tumor markers
No tumor markers speciﬁ  c to biliary tract cancer are 
available. Improved diagnostic ability can be achieved 
with a combination of tumor markers and other proce-
dures, but early diagnosis using tumor markers alone is 
difﬁ  cult
12,13,17–24 (levels II, III, IV).34  K. Tsukada et al.: Diagnosis of biliary cancer
with primary sclerosing cholangitis (PSC), in which it is 
demonstrated that, in regard to sensitivity and speciﬁ  c-
ity, three-dimensional CT (3 D-CT) is as useful as chol-
angiography in assessing this cancer
27 (level IV). On the 
other hand, it is also known that the diagnosis of bile 
duct cancer associated with PSC is difﬁ  cult. The pres-
ence of lymph node enlargement, which is useful for 
making a diagnosis of cancers, does not mean that there 
is malignancy, because lymph node enlargement also 
occurs in inﬂ  ammatory changes in PSC
28  level IV). 
Enhanced CT detect the lymph node swelling, however 
it is not effective in differentiating whether the swelling 
indicates an inﬂ  ammatory or a malignant change
29,30 
(level IV).
MRCP, endoscopic cholangiopancreatography (ERCP), 
and percutaneous transhepatic cholangiography (PTC) 
(Fig. 7)
MRCP is useful in identifying the site of bile duct stric-
ture, in diagnosing the extension of invasion, and in 
conﬁ  rming the presence or absence of abnormal pan-
creas and bile duct conﬂ  uence
31 (level IV). The sensitiv-
ity of MRCP in differentiating between benign and 
malignant bile duct strictures is 70%–96% and that in 
identifying the site of obstruction is 94%–99%.
32–34 
Therefore, MRCP is a recommendable procedure.
Although direct cholangiography modalities, such as 
ERCP and cholangiography using percutaneous tran-
shepatic biliary drainage (PTBD), are associated with 
a risk of incidental disease and are not necessarily 
required
35 (level IV), these modalities are useful for the 
diagnosis of the horizontal extension of nodules or the 
nodular invasive type of bile duct cancer
36,37 (level IV) 
(Fig. 8).
A cytologic diagnosis of bile can be carried out 
with the use of endoscopic retrograde cholangiography 
Fig. 5.  MDCT intersection image of the same patient as in Fig. 
4 (arterial phase) the right hepatic artery is adjacent to the 
tumor
Fig. 6.  MDCT intersection image of the same patient as in Fig. 
4 (venous phase) reconstructed along the left and right conﬂ  u-
ence of the hepatic duct. The portal vein runs parallel with the 
tumor
Fig. 4.  Multidetector computed tomography (MDCT) image 
of cancer of the hilar bile duct reconstructed along the left and 
right conﬂ  uence of the hepatic duct. It suggests invasion as 
well as thickening of the hepatic duct as far as the anterior 
and posterior segment branching
CT
Enhanced CT (multidetector computed tomography 
[MDCT] where available) enables the assessment of 
blood-ﬂ  ow dynamics in the bile duct wall and it is useful 
for making a diagnosis of the main invasion site (Fig. 4). 
However, there are cases in which no association of 
thickening of the bile duct wall is observed, so the use 
of CT alone is not sufﬁ  cient for a diagnosis of the precise 
degree of extension and depth of mural invasion
22,25 
(levels IV, II). A diagnosis of vascular invasion with the 
use of enhanced CT (MDCT where available) is of 
importance for decision-making in diagnostic policies 
(Figs. 5, 6)
22,25,26 (levels II-IV).
In Western countries, there are many studies of the 
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Fig. 7.  Percutaneous transhepatic cholangiography of cancer 
of the hilar bile duct (BD): the stricture has extended as far 
as the upper bile duct and the conﬂ  uence of the left and right 
hepatic duct. The middle and lower bile ducts and gallbladder 
are almost normal. Ant., anterior; post., posterior; B2, B3, 
and B4  indicate the segmental ducts of S2, S3, and S4, 
respectively
B2
B3
B4
B2
B3
B4
Fig. 8.  Percutaneous transhepatic biliary drainage (PTBD) 
cholangiography for nodular-inﬁ  ltrating type cholangiocarci-
noma. Ductal tapering due to cancer inﬁ  ltration is seen from 
the hepatic conﬂ  uence to the left hepatic duct (arrows). Right 
hepatectomy is required for curative resection; however, right 
trisectionectomy is necessary. B2, B3, and B4 indicate the seg-
mental ducts of S2, S3, and S4, respectively
(ERC), but the rate of accurate diagnosis using this 
procedure is approximately 30%. The rate increases by 
40%–70% by using brush biopsy
22 (level II).
Cholangioscopy
Percutaneous transhepatic cholangioscopy (PTCS) 
enables the detailed examination and direct-vision 
biopsy of the lumen of the bile duct. PTCS is useful in 
both differentiating benign and malignant biliary stric-
tures and in diagnosing the superﬁ  cial mucosal spread 
of cholangiocarcinoma along the bile duct wall.
38,39 
Peroral cholangioscopy (POCS) is useful in differentiat-
ing benign and malignant stenotic lesions of the bile 
duct;
40,41 however, it is not so feasible for close examina-
tion of the hilar bile duct due to its relatively poor 
operational performance.
41 Intraductal ultrasonography 
(IDUS) has advantages in both diagnosing the depth of 
invasion, including vascular invasion, and the intramural 
spread of cholangiocarcinoma along the bile duct 
wall.
42,43
Positron emission tomography (PET)
Although there are no deﬁ  nite opinions about the role 
of PET in the diagnosis of bile duct cancer, there is a 
report describing its usefulness in making a diagnosis of 
distant metastasis
44 (level III). The diagnostic capability 
of PET/CT is superior to that of CT alone with respect 
to distant metastatic lesions, but it is similar with respect 
to primary lesions
30 (level IV). Although PET/CT shows 
excellent diagnostic ability in detecting the mass-forming 
type of tumor, its usefulness in detecting the invasive 
type is poor
45 (level IV). There are almost no reports 
proving the usefulness of PET in differentiating PSC 
and bile duct cancer
46 (level III).
CQ 4  What is the second step in the diagnosis of 
gallbladder cancer?
In gallbladder cancer, the differential diagnosis and 
the diagnosis of the degree of extension of the cancer 
are of importance. Endoscopic ultrasonography 
(EUS) and CT (including MDCT) are recommended 
for both of these diagnoses (recommendation B).36  K. Tsukada et al.: Diagnosis of biliary cancer
Endoscopic ultrasonography (EUS)
Endoscopic ultrasonography (EUS) is an excellent pro-
cedure for depicting a protruded lesion in the gallblad-
der and the procedure can be conducted in an outpatient 
clinic. Its sensitivity in differentiating benign gallbladder 
disease from gallbladder cancer is reported to be excel-
lent, ranging from 92% to 97%
47,48  (level IV). It is 
reported that it is also useful for the diagnosis of the 
depth of mural invasion, the rate of accurate diagnosis 
being 100% for invasion limited to the mucosa (m) and 
muscularis propria (mp), and 75% for invasion limited 
to the subserosa (ss) and invasion of the serosal surface 
(se) or more; also, a diagnosis of the depth of mural 
invasion was possible in 13 of 14 patients receiving 
EUS
49 (level IV). Furthermore, there is also a report 
that in a case of pedunculated lesions (Ip), according 
to the classiﬁ  cation based on gross appearance, EUS 
showed that all of these lesions were cancers with inva-
sion limited to the mucosa
50 (level IV).
CT
There is a report showing that the sensitivity, speciﬁ  city, 
and accuracy of CT for a protruded lesion in the gall-
bladder is 88%, 87%, and 87%, respectively,
51  these 
values being lower than those of EUS. According to 
another report, the accuracy of diagnosis of invasion 
depth by helical CT is 86% for T1, 71% for T2, 81% for 
T3, and 95% for T4 tumors
52 (level IV). The accuracy of 
diagnosis of hepatic inﬁ  ltration was 81% for cases in 
which the tumor had inﬁ  ltrated the hepatic parenchyma 
less than 2 cm in length and 100% for cases with inﬁ  ltra-
tion of more than 2 cm
53 (level V).
The rate of detection
53 of lymph node metastasis with 
CT is reported to be 38%–65%
54,55 (level IV). As criteria 
for decisions on metastasis, Ohtani et al.
55 indicated that 
the metastasis should be, in anterior and posterior diam-
eter, larger than 10  mm and that the images achieved 
should be ring-like in shape or heterogeneous (level 
IV).
CT is inferior to EUS in its rate of accurate diagnosis 
of individual factors in the extension of the lesion. 
However, CT makes possible the assessment of images 
of all the surroundings of the lesion, and according to 
a report on resectability, the accuracy of diagnosis was 
93.3%
56 (level IV).
ERC
ERC is useful for assessing the invasion of tumor to the 
cystic duct and common hepatic duct
57,58 (level IV). As 
for the diagnosis of gallbladder cancer with ERC, the 
positive rate with the use of cytologic diagnosis is 
reported to be 45%–67%
59–62 (level IV).
MRI, MRCP
It is reported that the sensitivity of the diagnosis of 
hepatic inﬁ  ltration with MRI is 67%–100% and the 
speciﬁ  city is 89%; the sensitivity of invasion to the bile 
duct is 62%–100% and the speciﬁ  city is 56%–92%; and 
the sensitivity for lymph node metastasis is 56%–92% 
and the speciﬁ  city is 89%
63,64 (level IV).
PET
The assessment of PET or PET/CT in gallbladder cancer 
is similar to that noted above for the second step in bile 
duct cancer.
30,45
CQ 5 What is the second step in the diagnosis 
of ampullary carcinoma?
Tissue biopsy is conducted for tumor of the papilla 
(recommendation B). CT and MRI are performed for 
the diagnosis of distant metastasis and lymph node 
metastasis (recommendation B). Intraductal 
ultrasonography (IDUS) and EUS are useful for 
diagnosis of pancreatic and duodenal invasions 
(recommendation C1).
The rate of resection of ampullary carcinoma is high and 
the number of patients in whom this disease is unresect-
able due to local extension is small (level IV). Accord-
ing to the gross appearance (endoscopic characteristics) 
of the tumor (Figs. 9, 10), an ulcerative type tumor is 
often an advanced cancer,
65 so this type of tumor is not 
indicated for limited surgery. Therefore, a diagnosis 
should be made only concerning the suitability of resec-
tion. The diagnosis of distant metastasis, including liver 
metastasis, is now being made by US, CT, and MRI. 
Recent MDCT techniques
66 (level IV) enable the pro-
duction of three-dimensional images, which make clear 
the anatomical relationship (the presence or absence of 
invasion ) of a tumor with the bile duct and vessels.
Although ampullary carcinoma presents with symp-
toms such as jaundice, fever, and abdominal pain, tumor 
of the papilla is often suspected based on endoscopic 
and ultrasonographic ﬁ  ndings on the occasion of medical 
examination, which are followed by detailed examina-
tion. The second step in the diagnosis of a mass-forming 
type of tumor is to make a diagnosis of the presence or 
absence of cancer. Adenoma is indicated for resection 
because a cancer in adenoma,
67 in which cancer exists 
in a small region, is not infrequent (level IV). Biopsy is 
helpful in performing limited surgery for resection or 
endoscopic resection of the papilla. Many of the tumors 
for which endoscopic resection of the papilla
68 has been 
performed are adenomas. Although there are reports of K. Tsukada et al.: Diagnosis of biliary cancer  37
Fig. 9.  Macroscopic types of ampul-
lary tumors (with permission from the 
Japanese Society of Biliary Surgery. 
Classiﬁ  cation of biliary tract carci-
noma. Second English edition. Tokyo: 
Kanehara; 2004.)
a b
c d
e
g
f
Fig. 10a–g.  Gross ﬁ  ndings of 
ampullary carcinomas. a 
Nonexposed protruded type; 
b  exposed protruded type; 
c  tumor-ulcer type (predo-
minant protruded type); 
d tumor-ulcer type (predom-
inant ulcerative type); e 
ulcerative type; f   special 
type (normal-appearing 
type); g special type (polyp 
type) (with permission from 
the Japanese Society of 
Biliary Surgery. Classiﬁ  ca-
tion of biliary tract carci-
noma. Second English 
edition.  Tokyo: Kanehara; 
2004.)38  K. Tsukada et al.: Diagnosis of biliary cancer
cases of cancer in adenoma, they are concerned with 
discussions of only a small number of cases. A good 
outcome cannot be achieved for an advanced cancer 
with the use of limited surgery (level IV).
There are many reports comparing preoperative and 
postoperative stages with respect to diagnosis of the 
degree of local extension. It is consistently accepted that 
depicting tumors by means of US and CT is difﬁ  cult, but 
that tumors can be depicted with the use of EUS or 
IDUS
69,70 (level II). EUS is an excellent procedure to 
determine pancreatic invasion, but it is unable to deter-
mine histological pancreas invasion pPanc 1a (Table 3). 
There are also a number of reports demonstrating that 
determination of histological duodenal invasion (pDu 
1; Table 3) by EUS is also difﬁ  cult. In the present guide-
lines, histological determination was made according to 
the Japanese Society of Biliary Surgery Classiﬁ  cation of 
biliary tract carcinoma. Second English edition (Tokyo: 
Kanehara; 2004). Although IDUS is superior for making 
a diagnosis of extension to the pancreas duct or bile 
duct, pancreatic invasion, and duodenal invasion, the 
rate of accurate diagnosis being 80%–90%, the number 
of institutions employing EUS and IDUS is small. The 
use of IDUS has not been taken up widely yet.
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